Of these, the most significant was a Phase II study of the oral mTOR inhibitor, everolimus, in combination with capecitabine achieved an OS of 8.9 months in patients that presented with advanced pancreatic cancer (94% MPC) [29]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.